Notwithstanding positive clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable opposition from pharmacy benefit managers. These insurers https://phoenixcctd990066.topbloghub.com/48624222/company-s-drug-faces-is-meeting-managed-care-organization-hurdles-a-review-at-coverage-disputes